Literature DB >> 18630477

Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life.

Arndt Büssing1, Wilfried Tröger, Cristina Stumpf, Michael Schietzel.   

Abstract

BACKGROUND: In a previous study a decline of T-lymphocyte function was observed within a 6-month period of Viscum album extract (VA-E) application which did not occur in those patients with dose adaptation in response to strong local reactions (LR) or in those with moderate LR. To further investigate the immunological prerequisites of these differences in the VA-E susceptibilities, an analysis was carried out of the pre-existing differences in the tumor patients' lymphocyte subsets, and of whether the LR pattern (none, moderate, strong) might be associated with distinct aspects of the patients' quality of life. PATIENTS AND METHODS: Seventy-one cancer patients were subcutaneously treated with VA-E (Iscador) at increasing concentrations and their lymphocyte subsets measured by flowcytometry during a 6 month observation period; quality of life was assessed with the HLQ questionnaire.
RESULTS: The occurrence of stronger LR was associated with a primarily higher level of T-cells and their CD4+ T-helper/inducer subset, and CD25+ respectively HLA-DR+ (activated) T-cells. Moreover, counts or proportions of T-cells, CD4+ T-helper/inducer cells and CD8+ CD28+ cytotoxic cells were lower, while the relative proportions of CD8+ CD28- suppressor cells, B- and NK-cells were the highest in the group with moderate LR. In particular, this latter group had a significantly higher quality of life.
CONCLUSION: Our results indicate that the induction of moderate LR in response to VA-E application was associated with better T cell function and quality of life. Extracts from Viscum album (VA-E) are widely used as a

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630477

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis.

Authors:  Arndt Büssing; Christa Raak; Thomas Ostermann
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-14       Impact factor: 2.629

2.  Adverse drug reactions in a complementary medicine hospital: a prospective, intensified surveillance study.

Authors:  M Süsskind; P A Thürmann; C Lüke; E Jeschke; M Tabali; H Matthes; T Ostermann
Journal:  Evid Based Complement Alternat Med       Date:  2012-01-17       Impact factor: 2.629

Review 3.  Preclinical and clinical effects of mistletoe against breast cancer.

Authors:  Mohsen Marvibaigi; Eko Supriyanto; Neda Amini; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

4.  Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study.

Authors:  Shiao Li Oei; Anja Thronicke; Matthias Kröz; Harald Matthes; Friedemann Schad
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

5.  Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy.

Authors:  Guo-Shiou Liao; Maria Karmella Apaya; Lie-Fen Shyur
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-12       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.